PDF(Pubmed)
Abstract：
Pancreatic cancer is difficult to diagnose early and progresses rapidly. Researchers have found that a cytokine called Interleukin-6 (IL-6) is involved in the entire course of pancreatic cancer, promoting its occurrence and development. From the earliest stages of pancreatic intraepithelial neoplasia to the invasion and metastasis of pancreatic cancer cells and the appearance of tumor cachexia, IL-6 drives oncogenic signal transduction pathways and immune escape that accelerate disease progression. IL-6 is considered a biomarker for pancreatic cancer diagnosis and prognosis, as well as a potential target for treatment. IL-6 antibodies are currently being explored as a hot topic in oncology. This article aims to systematically explain how IL-6 induces the deterioration of normal pancreatic cells, with the goal of finding a breakthrough in pancreatic cancer diagnosis and treatment.
摘要：
胰腺癌难以早期诊断且进展迅速。研究人员发现，一种称为白细胞介素-6（IL-6）的细胞因子参与胰腺癌的整个过程，促进其发生和发展。从胰腺上皮内瘤变的最早阶段到胰腺癌细胞的侵袭和转移以及肿瘤恶病质的出现，IL-6驱动致癌信号转导途径和加速疾病进展的免疫逃逸。IL-6被认为是胰腺癌诊断和预后的生物标志物。以及潜在的治疗目标。IL-6抗体目前正在作为肿瘤学的热门话题进行研究。本文旨在系统地解释IL-6如何诱导正常胰腺细胞的退化。目的是在胰腺癌的诊断和治疗方面取得突破。
